Correction to: Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-2027
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Correction to: Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study ; volume:39 ; number:9 ; day:19 ; month:6 ; year:2021 ; pages:1099 ; date:9.2021
PharmacoEconomics ; 39, Heft 9 (19.6.2021), 1099, 9.2021
- Creator
-
Pennington, Becky
Alshreef, Abualbishr
Flight, Laura
Metry, Andrew
Poku, Edith
Hykin, Philip
Sivaprasad, Sobha
Prevost, A. Toby
Vasconcelos, Joana C.
Murphy, Caroline
Kelly, Joanna
Yang, Yit
Lotery, Andrew J.
Williams, Michael
Brazier, John
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40273-021-01057-y
- URN
-
urn:nbn:de:101:1-2021103110184211315108
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:26 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Pennington, Becky
- Alshreef, Abualbishr
- Flight, Laura
- Metry, Andrew
- Poku, Edith
- Hykin, Philip
- Sivaprasad, Sobha
- Prevost, A. Toby
- Vasconcelos, Joana C.
- Murphy, Caroline
- Kelly, Joanna
- Yang, Yit
- Lotery, Andrew J.
- Williams, Michael
- Brazier, John
- SpringerLink (Online service)
Other Objects (12)
Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study
Formulation Stabilization and Disaggregation of Bevacizumab, Ranibizumab and Aflibercept in Dilute Solutions
Hydrodynamic Radii of Ranibizumab, Aflibercept and Bevacizumab Measured by Time-Resolved Phosphorescence Anisotropy
Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab
Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD
Intravitreal aflibercept and ranibizumab for pachychoroid neovasculopathy
Real-World Results of Switching Treatment from Ranibizumab to Aflibercept in Macular Oedema Secondary to Branch Retinal Vein Occlusion
Photokinetic Drug Delivery: Near infrared (NIR) Induced Permeation Enhancement of Bevacizumab, Ranibizumab and Aflibercept through Human Sclera
How Successful is Switching from Bevacizumab or Ranibizumab to Aflibercept in Age-Related Macular Degeneration? A Systematic Overview
Erratum für: Das klinische Ergebnis eines Therapiewechsels von Ranibizumab und/oder Bevacizumab zu Aflibercept bei neovaskulärer altersabhängiger Makuladegeneration (AMD)
Auswirkungen von intravitrealem Ranibizumab, Aflibercept und Bevacizumab auf die Dicke der retinalen Ganglienzell- und Nervenfaserschicht bei neovaskulärer altersbedingter Makuladegeneration
Conversion back to bevacizumab or ranibizumab for recurrent neovascular activity with aflibercept in age-related macular degeneration: a case series
Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study
Formulation Stabilization and Disaggregation of Bevacizumab, Ranibizumab and Aflibercept in Dilute Solutions
Hydrodynamic Radii of Ranibizumab, Aflibercept and Bevacizumab Measured by Time-Resolved Phosphorescence Anisotropy
Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab
Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD
Intravitreal aflibercept and ranibizumab for pachychoroid neovasculopathy
Real-World Results of Switching Treatment from Ranibizumab to Aflibercept in Macular Oedema Secondary to Branch Retinal Vein Occlusion
Photokinetic Drug Delivery: Near infrared (NIR) Induced Permeation Enhancement of Bevacizumab, Ranibizumab and Aflibercept through Human Sclera
How Successful is Switching from Bevacizumab or Ranibizumab to Aflibercept in Age-Related Macular Degeneration? A Systematic Overview
Erratum für: Das klinische Ergebnis eines Therapiewechsels von Ranibizumab und/oder Bevacizumab zu Aflibercept bei neovaskulärer altersabhängiger Makuladegeneration (AMD)
Auswirkungen von intravitrealem Ranibizumab, Aflibercept und Bevacizumab auf die Dicke der retinalen Ganglienzell- und Nervenfaserschicht bei neovaskulärer altersbedingter Makuladegeneration
Conversion back to bevacizumab or ranibizumab for recurrent neovascular activity with aflibercept in age-related macular degeneration: a case series
Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study
Formulation Stabilization and Disaggregation of Bevacizumab, Ranibizumab and Aflibercept in Dilute Solutions
Hydrodynamic Radii of Ranibizumab, Aflibercept and Bevacizumab Measured by Time-Resolved Phosphorescence Anisotropy
Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab
Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD
Intravitreal aflibercept and ranibizumab for pachychoroid neovasculopathy
Real-World Results of Switching Treatment from Ranibizumab to Aflibercept in Macular Oedema Secondary to Branch Retinal Vein Occlusion
Photokinetic Drug Delivery: Near infrared (NIR) Induced Permeation Enhancement of Bevacizumab, Ranibizumab and Aflibercept through Human Sclera
How Successful is Switching from Bevacizumab or Ranibizumab to Aflibercept in Age-Related Macular Degeneration? A Systematic Overview
Erratum für: Das klinische Ergebnis eines Therapiewechsels von Ranibizumab und/oder Bevacizumab zu Aflibercept bei neovaskulärer altersabhängiger Makuladegeneration (AMD)
Auswirkungen von intravitrealem Ranibizumab, Aflibercept und Bevacizumab auf die Dicke der retinalen Ganglienzell- und Nervenfaserschicht bei neovaskulärer altersbedingter Makuladegeneration